论文部分内容阅读
狂犬病病毒接触病人接种疫苗后7天内产生的中和抗体不高于0.5IU/ml,而该浓度的抗体可阻止病毒侵袭外周神经细胞从而提供保护作用.为了解疫苗接种后3～5天内注射狂犬病免疫球蛋白(RIG)对人体中和抗体应答影响,作者采用泰国红十字会推荐的暴露后皮内接种的方案(TRC-ID)进行研究,即于感染后0、3、7天分别于两个部位皮内接种0.1ml疫苗,并于28、90天分别于1个部位皮内接种0.1ml疫苗.作者将48名受试者分为3组.A组18名严重暴露者(WHO分类为Ⅲ型暴露者)在接种疫苗的同时于伤口部位注射40IU/kg的RIG.B组16名WHO分类为Ⅱ型暴露者于接种疫苗后3天肌肉注射40IU/kg的RIG.C组14名未接触病毒的志愿者于接种疫苗后5天肌肉注射40IU/kg的RIG.用快速免疫荧光灶抑制试验测定中种抗体.结果所有受试者在14～28天时中和抗体滴度均>0.5IU/ml.三组的抗体几何平均滴度(GMT)无明显差异,但第7天B组抗体GMT明显低于A组.A组受试者6个月后抗体滴度均>0.5IU/ml.但B组14人中分别有4人和1人在第90、180天时抗体滴度<0.5IU/ml.
The neutralizing antibody produced by rabies virus-exposed patients within 7 days after vaccination is not higher than 0.5 IU / ml, and the antibody at this concentration can prevent the virus from attacking the peripheral nerve cells to provide a protective effect.In order to know the rabies-infected rabies is injected within 3 to 5 days after vaccination Immunoglobulin (RIG) on human neutralizing antibody response, the authors use the Thai Red Cross recommended after intradermal vaccination program (TRC-ID) study, that is, 0,3,7 days after infection in the two 0.1 ml vaccine was intradermally inoculated with 0.1 ml vaccine intradermally in one site on days 28 and 90. The 48 subjects were divided into 3 groups, 18 in group A (WHO classified as Type III exposed) were injected with 40 IU / kg of RIG at the site of the wound at the time of vaccination Group B 16 WHO classified as Type II exposed intramuscularly 40 IU / kg of RIG.C 14 days after vaccination Volunteers exposed to the virus were intramuscularly injected with 40 IU / kg of RIG 5 days after vaccination. The inbred antibody was determined by a rapid immunofluorescence stain inhibition test Results All subjects had neutralizing antibody titers> 0.5 IU at 14-28 days / ml.The three groups of antibody geometric mean titer (GMT) no significant difference, but on the 7th day B The antibody titer of GMT in group A was significantly lower than that in group A. The titer of antibody in group A was> 0.5 IU / ml after 6 months, but in group B, there were 4 and 1, respectively. At day 90 and 180, <0.5 IU / ml.